About US
Contact us
-
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?Bristol-Myers Squibb’s Thursdayannouncementthat it would nab Celgene for $74 billion brought “megamergers back to pharma,” as Credit Suisse analyst Vamil Divan put it in a note to clients. And the ret2019/1/8
-
AstraZeneca’s Fasenra puts more pressure on GSK’s Nucala with expanded NICE backingBack in mid-2018, AstraZeneca’s Fasenra hit a speed bump as England’s drug cost watchdog recommended it only when GlaxoSmithKline’s rival asthma drug Nucala wasn’t appropriate. But now, the AZ drug is2019/1/7
-
Fujifilm plans $20M U.S. facility for burgeoning interest in stem cell treatmentsA host of companies are developing regenerative treatments that lean on stem cells. Seeing an opportunity, Japan’s Fujifilm will build a U.S. stem cell manufacturing facility not only for its own effo2019/1/7
-
Ex-Teva chairman Phillip Frost pays $5.5M to settle 'pump-and-dump' chargesHealthcare billionaire and former Teva chairman Philip Frost has agreed to settle stock “pump-and-dump” charges with the Securities and Exchange Commission by paying $5.5 million. Frost, without admi2019/1/4
-
Pharma raises prices to ring in 2019. Will it trigger action in Washington?It’s a new year, and many top pharma companies are taking the opportunity to raise prices for their big sellers. As the industry has in the past, several drugmakers opted to raise prices to ring in 202019/1/4
-
Pfizer, Merck shares smoking hot in 2018 despite doldrums for overall biopharma sectorBy the end of the last full week of 2018, the two best performers on the Dow Jones Industrial Average for the year were Pfizer and Merck & Co., up 22% and 38% respectively. The two pharma bigwigs2019/1/3
-
French inspectors find issues at Indian plant cited earlier by ItalyFrench inspectors found a lot they didn’t like about an Indian manufacturer when they inspected its operation for consideration of approving its ambroxol hydrochloride API. The problems led the Europe2019/1/3
-
FiercePharmaAsia—Possible Sun probe; Huahai warning letter; Eisai-UCL neuro pactThe possibility of a government investigation looms ever larger for Sun Pharma, as Indian regulators said they're indeed reviewing whistleblower allegations against the company. In a newly posted warn2019/1/2
-
Whistleblower complaint against Sun Pharma confirmed by Indian regulators: reportSun Pharma drew more unwanted attention this weekwhen India’s stock regulators confirmed they are examining whistleblower allegations against the company. “We have received the complaint against Sun2019/1/2
-
The valsartan carcinogen mess taught pharma a surprise manufacturing lesson. Will 2019 bring more?Industry wisdom is that there is nothing new to learn about tablet making. Drugmakers have been doing it essentiallythe same way for more than 100 years. But that idiom was turned on its head this yea2018/12/25